Alimera Sciences

Retinal Disease
is Our Focus

Moving the back of the eye to the forefront
of research and development.

Learn more about our goals »

ILUVIEN: Investigational Treatment for DME

ILUVIEN® Fluocinolone acetonide intravitreal insert .019 mg

ILUVIEN® has received its marketing authorization approval in Austria, France, Germany, Portugal, Spain and the United Kingdom and is going through the national phase in the approval process in Italy. Alimera Sciences is still seeking approval in the United States.

Learn more >

Diabetes is the leading cause of new cases of blindness in adults

DIABETES and
VISION LOSS

Diabetes is the leading cause of new cases of blindness in adults.

Learn More >

Latest News

View All Recent News »

Alimera Sciences Announces New PDUFA Date For ILUVIEN®

April 14, 2014 --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug...

Read More »

Alimera Sciences Announces Resubmission Of ILUVIEN® New Drug Application To FDA

March 27, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for...

Read More »

Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference

February 28, 2014 --  Alimera Sciences, Inc. (Nasdaq: ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive...

Read More »